Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan for Hospitalized COVID-19 Patients
NCT04715763Phase 2Terminated
- Sponsor
- University of Hawaiʻi
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Telmisartan Arm with Placebo Arm (2 arms). Primary endpoint: Duration of hospitalization at 21 days. Started Sep 2021; status: terminated.
02
Drugs
telmisartan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04715763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715763.